RxDoctor Payments Data

Hassan Chahadeh, MD

Interventional Pain Medicine · Houston, TXNPI 1730124470

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (34.7%), travel and lodging and entertainment — rather than concentrated in one kind of arrangement. Stimwave Technologies Incorporated accounts for 74.4% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2019 at $12,239 and has fallen 93.2% since, to $836 in 2025.

$15,800in general payments, 2019–2025

Across 110 payments — averaging $143.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stimwave Technologies Incorporated$12K
  • Nevro Corp.$637
  • Abbott$594
  • Bioness Inc$554
  • Zynex Medical, Inc.$501
  • Si-bone, Inc.$397
  • plus $1K from 17 others

What the payments were for

  • Travel & lodging$5,02532%
  • Food & beverage$5,47535%
  • Gifts$2992%
  • Entertainment$5,00132%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,800 in reported general payments places this provider in the 70th percentile of 287 interventional pain medicine providers in Texas.

See all interventional pain medicine providers in Texas →

Medicare billing

Part B allowed, 2024
$112,535
Medicare patients
191
Services billed
956

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NucyntaTapentadol Hcl13$26,387
Buprenorphine46$7,634
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen186$6,655
Sumatriptan Succinate27$4,387
Acetaminophen-CodeineAcetaminophen With Codeine172$3,410
Lidocaine48$3,394
Tizanidine Hcl435$3,143
Gabapentin236$2,602
Cyclobenzaprine Hcl118$948
Pregabalin34$796
Diclofenac Sodium33$673
Methocarbamol17$357
Celecoxib25$344
Tramadol Hcl-AcetaminophenTramadol Hcl/Acetaminophen49$324
Meloxicam132$323

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Nucynta$70$26,38713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 287 interventional pain medicine providers in Texas.

Other interventional pain medicine in Houston

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →